Cue Biopharma, Inc.CUEEarnings & Financial Report
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CUE Q4 FY2025 Key Financial Metrics
Revenue
$21.9M
Gross Profit
N/A
Operating Profit
$2.0M
Net Profit
$1.6M
Gross Margin
N/A
Operating Margin
9.0%
Net Margin
7.2%
YoY Growth
1292.3%
EPS
$0.05
Cue Biopharma, Inc. Q4 FY2025 Financial Summary
Cue Biopharma, Inc. reported revenue of $21.9M (up 1292.3% YoY) for Q4 FY2025, with a net profit of $1.6M (up 116.7% YoY) (7.2% margin).
Key Financial Metrics
| Total Revenue | $21.9M |
|---|---|
| Net Profit | $1.6M |
| Gross Margin | N/A |
| Operating Margin | 9.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Cue Biopharma, Inc. Q4 FY2025 revenue of $21.9M breaks down across 3 segments, led by Immuno Scape Collaboration And License Agreement at $9.5M (43.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Immuno Scape Collaboration And License Agreement | $9.5M | 43.3% |
| BI Collaboration And License Agreement | $8.1M | 36.9% |
| Other | $4.3M | 19.8% |
Cue Biopharma, Inc. Annual Revenue by Year
Cue Biopharma, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $27.5M).
Cue Biopharma, Inc. Quarterly Revenue & Net Profit History
Cue Biopharma, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.9M | +1292.3% | $1.6M | 7.2% |
| Q3 FY2025 | $2.1M | -35.6% | $-7.4M | -346.6% |
| Q2 FY2025 | $3.0M | +11.1% | $-8.5M | -287.1% |
| Q1 FY2025 | $421.0K | -75.5% | $-12.3M | -2911.4% |
| Q4 FY2024 | $1.6M | -13.5% | N/A | N/A |
| Q3 FY2024 | $3.3M | +58.9% | $-8.7M | -259.6% |
| Q2 FY2024 | $2.7M | +92.3% | $-10.2M | -382.7% |
| Q1 FY2024 | $1.7M | +818.2% | $-12.3M | -719.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $2.7M | $3.3M | $1.6M | $421000 | $3.0M | $2.1M | $21.9M |
| YoY Growth | 818.2% | 92.3% | 58.9% | -13.5% | -75.5% | 11.1% | -35.6% | 1292.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $54.0M | $42.3M | $44.8M | $32.2M | $22.3M | $40.7M | $31.6M | $42.2M |
| Liabilities | $23.9M | $20.7M | $19.4M | $14.7M | $15.7M | $22.5M | $18.4M | $15.8M |
| Equity | $30.0M | $21.6M | $25.4M | $17.5M | $6.6M | $18.2M | $13.2M | $26.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.8M | $-10.0M | $-7.5M | $-36.3M | $-8.2M | $-3.4M | $-9.0M | $-1.1M |